These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 16870084)
1. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Maniadakis N; Tzanakis N; Fragoulakis V; Hatzikou M; Siafakas N Curr Med Res Opin; 2006 Aug; 22(8):1599-607. PubMed ID: 16870084 [TBL] [Abstract][Full Text] [Related]
2. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM Value Health; 2005; 8(1):32-46. PubMed ID: 15841892 [TBL] [Abstract][Full Text] [Related]
3. Which long-acting bronchodilator is most cost-effective for the treatment of COPD? Hoogendoorn M; Kappelhoff BS; Overbeek JA; Wouters EF; Rutten-van Mölken MP Neth J Med; 2012 Oct; 70(8):357-64. PubMed ID: 23065983 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844 [TBL] [Abstract][Full Text] [Related]
5. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Rutten-van Mölken MP; Oostenbrink JB; Miravitlles M; Monz BU Eur J Health Econ; 2007 Jun; 8(2):123-35. PubMed ID: 17370096 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Oba Y Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795 [TBL] [Abstract][Full Text] [Related]
7. [Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease]. Schramm W; Haake D; Brandt A Praxis (Bern 1994); 2005 Nov; 94(46):1803-10. PubMed ID: 16329401 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. Sun SX; Marynchenko M; Banerjee R; Cheng D; Mocarski M; Yin D; Yu AP; Wu EQ J Med Econ; 2011; 14(6):805-15. PubMed ID: 21992217 [TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Najafzadeh M; Marra CA; Sadatsafavi M; Aaron SD; Sullivan SD; Vandemheen KL; Jones PW; Fitzgerald JM Thorax; 2008 Nov; 63(11):962-7. PubMed ID: 18621985 [TBL] [Abstract][Full Text] [Related]
10. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM; N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Lee KH; Phua J; Lim TK Respir Med; 2006 Dec; 100(12):2190-6. PubMed ID: 16635566 [TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Price D; Gray A; Gale R; Asukai Y; Mungapen L; Lloyd A; Peters L; Neidhardt K; Gantner T Respir Med; 2011 Nov; 105(11):1635-47. PubMed ID: 21764277 [TBL] [Abstract][Full Text] [Related]
14. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease. Somand H; Remington TL Ann Pharmacother; 2005 Sep; 39(9):1467-75. PubMed ID: 16030078 [TBL] [Abstract][Full Text] [Related]
15. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD. Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631 [TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol]. García Ruiz AJ; Leiva Fernández F; Martos Crespo F Arch Bronconeumol; 2005 May; 41(5):242-8. PubMed ID: 15919004 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Oba Y Mayo Clin Proc; 2007 May; 82(5):575-82. PubMed ID: 17493425 [TBL] [Abstract][Full Text] [Related]
18. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone. Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650 [TBL] [Abstract][Full Text] [Related]
19. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients. Vogelmeier C; Fabbri LM; Rabe KF; Beeh KM; Schmidt H; Metzdorf N; Glaab T Respir Med; 2013 Jan; 107(1):75-83. PubMed ID: 23102611 [TBL] [Abstract][Full Text] [Related]